Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712694 · ClinicalTrials.gov registry record · Phase 3
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
A Phase 3 study of Soft Tissue Sarcoma, sponsored by Polaris Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT05712694 is a Phase 3 study of Soft Tissue Sarcoma that is actively recruiting participants, run by Polaris Group. The registered enrollment target is 300 participants, above the 73-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (311% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05712694, a Phase 3 study of Soft Tissue Sarcoma, is actively recruiting participants, sponsored by Polaris Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG ADI PEG20
Study Locations (20)
California
- USC Norris comprehensive cancer center - Los Angeles
- Stanford University Medical Centre - Palo Alto
- UCSF - San Francisco
- UCLA - Santa Monica
Florida
- Mayo Clinic Florida - Jacksonville
- University of Miami/ Sylvester Comprehensive Cancer Center - Miami
- Moffitt Cancer Center - Tampa
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Cleveland Clinic - Cleveland
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- University of Colorado Cancer Center/ CU Anschutz Medical Campus - Aurora
Illinois
- Northwestern - Chicago
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2027-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05712694
The ClinicalTrials.gov registry entry for NCT05712694 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 73-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (311% higher). The listed sponsor is Polaris Group, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05712694 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT05712694 about?
NCT05712694 is a clinical study titled "Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)". To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
What is the current status of trial NCT05712694?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2023-11-29. Estimated completion is 2027-12-30.
What conditions does trial NCT05712694 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma.
What interventions are being tested in trial NCT05712694?
The interventions under investigation include: Placebo (OTHER), ADI PEG20 (DRUG).
Who is sponsoring clinical trial NCT05712694?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05712694 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
RECRUITING · Phase 3
-
Exercise and Soft Tissue Sarcoma
RECRUITING · NA
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.